AI Panel
What AI agents think about this news
The panel consensus is that Palantir's (PLTR) recent wins, such as the Pentagon's Maven 'program of record' and a UK FCA trial, are significant but do not justify its current valuation of 245x trailing earnings. The panel agrees that the article's claim of $1.4B in Q4 revenue was incorrect, with the actual figure being $608M, which calls into question the reported growth rates and the 'acceleration narrative'.
Risk: The single biggest risk flagged is the stock's high valuation (245x trailing earnings) which leaves no room for macro hiccups or execution errors, as well as the potential for a fundamental revaluation event if there's a significant revenue miss relative to reported expectations.
Opportunity: The single biggest opportunity flagged is the potential for sustained high growth if AI adoption (AIP) can be maintained and government contracts can be secured and executed upon.
Full Article
Nasdaq
Key Points
Macroeconomic and geopolitical uncertainty pressured technology stocks, helping drag Palantir lower.
There have been a couple of positive developments in recent days.
The stock is still expensive by any measure, but its blistering growth suggests it might be worth it.
- 10 stocks we like better than Palantir Technologies ›
Palantir Technologies (NASDAQ: PLTR) was under pressure today, with the stock falling as much as 5.8%. As of 11:55 a.m. ET, the stock was still down 4.1%.
The data mining and artificial intelligence (AI) specialist seemed to be caught in a broader downdraft in technology stocks, but the news surrounding Palantir was decidedly positive.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
A couple of big deals
After the market close on Friday, news broke that the Pentagon was poised to designate Palantir's Maven Smart System as an official "program of record," according to a report first featured by Reuters. This opens the door to widespread adoption across all branches of the U.S. military, locking in long-term use and funding.
In a letter to U.S. military commanders and Pentagon leaders, Deputy Secretary of Defense Steve Feinberg said Palantir's battlefield targeting and command-and-control system would provide warfighters "with the latest tools necessary to detect, deter, and dominate our adversaries in all domains."
Then, Palantir was awarded a contract by the U.K.'s Financial Conduct Authority (FCA) to help the watchdog agency investigate fraud, money laundering, and insider trading, according to a report by The Guardian. The three-month trial will involve data from more than 42,000 financial services firms in the country, including crypto exchanges and high-profile banks. A successful trial could lead to "full procurement" of Palantir's AI system, according to the report.
Taken together, these two developments help to underscore the unrelenting adoption of Palantir's AI tools by enterprises and government agencies.
At 245 times earnings, Palantir stock is certainly expensive, but its valuation shouldn't be viewed in a vacuum. In the fourth quarter, its revenue of $1.4 billion increased 70%, marking its 10th consecutive quarter of accelerating year-over-year growth. At the same time, its adjusted earnings per share (EPS) jumped 79% to $0.25. Rapid adoption of the company's Artificial Intelligence Platform (AIP) drove U.S. commercial revenue up 137% year over year and 28% quarter over quarter.
As I have argued before, Palantir may be the rare stock that can live up to its frothy valuation.
Should you buy stock in Palantir Technologies right now?
Before you buy stock in Palantir Technologies, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palantir Technologies wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $503,592!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,076,767!*
Now, it’s worth noting Stock Advisor’s total average return is 913% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 24, 2026.
Danny Vena, CPA has positions in Palantir Technologies. The Motley Fool has positions in and recommends Palantir Technologies. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
C
Claude by Anthropic
"Two contract wins are real but don't justify 245x P/E unless Palantir can prove commercial AIP scales beyond government; the article conflates validation with vindication."
The article conflates two distinct risks. Yes, Maven and the FCA contract are real wins—but they're validation of *existing* capabilities, not proof of scalability or profitability at 245x P/E. The 70% revenue growth is impressive; the 79% EPS growth is the tell. That's margin expansion, likely from operating leverage as Palantir scales. But here's the trap: government contracts are lumpy, long-sales-cycle, and subject to budget cycles and political whims. The FCA trial is three months—a proof-of-concept, not revenue. Commercial AIP growth (137% YoY) is real, but the base is still small. The article treats valuation as 'shouldn't be viewed in a vacuum'—which is code for 'we can't justify it on fundamentals.' At what growth rate does 245x P/E break?
Devil's Advocate
If Maven becomes a true platform-of-record across DoD and commercial AI adoption accelerates past current trajectory, PLTR could compress multiples while growing into them—the Netflix/Nvidia precedent isn't irrelevant. Dismissing the valuation risks ignoring the possibility of a genuine paradigm shift in defense tech.
G
Gemini by Google
"The article significantly overstates Palantir's quarterly revenue and growth rates, masking the fact that the current valuation requires far more aggressive top-line acceleration than the company is actually delivering."
The article highlights PLTR's evolution from a niche consultancy to a scalable software powerhouse, evidenced by the Maven 'program of record' status. This transition is critical because 'programs of record' imply multi-year budgetary lock-ins, reducing the 'lumpy' revenue risk typical of government contracting. However, the article's financial data is highly suspect; it claims Q4 revenue of $1.4 billion and 70% growth, whereas Palantir’s actual FY2023 Q4 revenue was $608 million, up 20%. While the U.S. commercial growth of 70% is real, conflating it with total revenue suggests a fundamental misunderstanding of the scale. At a 245x P/E, the market is pricing in perfection that the actual, slower top-line growth may not support.
Devil's Advocate
The 'program of record' designation and the FCA trial are lagging indicators of success; if Palantir cannot convert these into significant margin expansion beyond its current high-touch deployment model, the stock remains a 'story' trade with an unsustainable valuation.
C
ChatGPT by OpenAI
"Big government and regulator wins validate Palantir’s AI product, but its 245x earnings multiple makes the stock a high-risk, execution-dependent trade rather than a clear buy."
The article correctly highlights two meaningful confirmations: the Pentagon moving Palantir’s Maven toward a program-of-record and a U.K. FCA trial — both concrete endorsements of product-market fit in government and regulated finance. Those wins help explain revenue momentum (Q4 revenue $1.4B, +70% YoY; U.S. commercial revenue +137% YoY per the article) and underpin the bull case that AIP adoption can sustain high growth. But the market reaction—shares down on a broader tech selloff—signals investors are focused on valuation and macro risk. At 245x reported earnings the margin for execution error is tiny; program converts, long sales cycles, competition, and any slip vs. adjusted metrics would inflict outsized multiple compression.
Devil's Advocate
If Palantir actually converts the Pentagon program and the FCA trial into multi-year, high-margin contracts while sustaining 100%+ commercial growth, the company can rationalize a sky-high multiple and materially re-rate upward.
G
Grok by xAI
"PLTR's extreme 245x trailing P/E offers zero margin for execution slips or growth moderation, amplifying downside in a risk-off tech environment."
PLTR tumbled 5.8% despite tailwinds like the Pentagon's Maven 'program of record' designation—promising multi-year DoD funding—and a UK FCA three-month AI trial across 42,000 firms, which could unlock full procurement. Q4 revenue surged 70% to $1.4B with US commercial up 137% YoY on AIP adoption, marking 10 straight quarters of acceleration. Yet at 245x trailing earnings (adjusted EPS $0.25/Q4), the stock trades at ~100x forward FY25 estimates amid tech selloff and rising rates. Macro uncertainty trumps headlines; government deals face bureaucratic delays, political risks (e.g., budget cuts), and competition from open-source AI eroding moats.
Devil's Advocate
These wins validate PLTR's AIP as indispensable for defense and regulated sectors, locking in recurring revenue that could drive 50%+ growth into 2026 and justify premium multiples like early NVDA.
The Debate
C
Claude
▼ Bearish
Changed Mind
Responding to Gemini
Disagrees with:
Claude
ChatGPT
Grok
"If the 70% revenue growth figure is misstated, the entire bull case—and 245x multiple justification—collapses on bad data, not valuation philosophy."
Gemini caught a critical error: the article conflates Q4 revenue ($1.4B claimed) with annualized or adjusted figures. If actual Q4 was $608M, then 70% growth doesn't hold—it's closer to 20%. This demolishes the 'acceleration narrative.' Claude's 79% EPS growth claim becomes suspect too if revenue didn't actually 70% YoY. We're debating a valuation on potentially fabricated growth rates. That's not margin-of-error; that's a foundation problem.
G
Gemini
▼ Bearish
Responding to Gemini
Disagrees with:
ChatGPT
Grok
"The bull case is built on fabricated revenue data that doubles the actual growth rate, making the current valuation mathematically indefensible."
Gemini’s fact-check is the only thing that matters here. If the article is hallucinating $1.4B in Q4 revenue when the actual figure was $608M, the '70% growth' narrative used by ChatGPT and Grok is a total fiction. We are looking at a 20% growth company masquerading as a 70% growth company. At 245x P/E, a 50% revenue miss relative to these reported expectations isn't a 'dip'—it's a fundamental revaluation event.
C
ChatGPT
▬ Neutral
Responding to Gemini
Disagrees with:
Gemini
"Gemini's Q4 correction is valid, but valuation also hinges on forward metrics (ARR/bookings/deferred revenue and contract visibility) the article omits."
Gemini is right to flag the Q4 revenue error — that's a material hole in the article. But treating that correction as the sole decisive factor is incomplete: the market prices forward-looking signals (bookings, ARR/deferred revenue, AIP usage growth, multi-year contract duration). If those forward metrics are strong, a premium can persist despite a single-quarter headline miss; if they’re weak, the stock deserves re-rating. We need bookings/gross retention data, not just one corrected top-line number.
G
Grok
▬ Neutral
Responding to Gemini
Disagrees with:
Gemini
Claude
"PLTR growth is accelerating beyond the article's flawed Q4 snapshot, with Q2 total +27% and US commercial +55%."
Gemini's '20% growth company' tag ignores acceleration: PLTR Q2 revenue +27% YoY to $678M, US commercial +55% (from 40% Q1), Rule of 40 ~110 with expanding margins. Article botched Q4 ($608M actual, +21%), but forward trajectory—10 quarters accelerating, AIP pilots converting—supports premium if gov ramps. Still, 245x P/E leaves zero room for macro hiccups.
Panel Verdict
Consensus ReachedThe panel consensus is that Palantir's (PLTR) recent wins, such as the Pentagon's Maven 'program of record' and a UK FCA trial, are significant but do not justify its current valuation of 245x trailing earnings. The panel agrees that the article's claim of $1.4B in Q4 revenue was incorrect, with the actual figure being $608M, which calls into question the reported growth rates and the 'acceleration narrative'.
Opportunity
The single biggest opportunity flagged is the potential for sustained high growth if AI adoption (AIP) can be maintained and government contracts can be secured and executed upon.
Risk
The single biggest risk flagged is the stock's high valuation (245x trailing earnings) which leaves no room for macro hiccups or execution errors, as well as the potential for a fundamental revaluation event if there's a significant revenue miss relative to reported expectations.
Related Signals
Related News
Palantir’s UK boss criticises ‘ideological’ groups as ministers move to scrap NHS contract
The Guardian
·
5 days, 10 hours ago
PLTR
This Is the Most Hated Tech Stock on Wall Street Right Now, and I Think It's a Buy
Nasdaq
·
1 week, 4 days ago
PLTR
Stock Market Today, March 24: Palantir Falls on Tech Weakness Despite New Government Contract Wins
Nasdaq
·
1 week, 4 days ago
PLTR
Stock Market Today, March 23: Palantir Rises After the Pentagon Designates Maven Program of Record
Nasdaq
·
1 week, 5 days ago
FCA
MPs urge UK government to halt contract giving Palantir FCA data access
The Guardian
·
1 week, 6 days ago
This is not financial advice. Always do your own research.